Quantcast

Latest cancer therapies Stories

2011-01-16 00:23:26

The Integrative Cancer Therapies Fellowship with the American Academy of Anti-Aging Medicine (A4M) announces that Dr. Mark Rosenberg, Medical Director of the Institute for Healthy Aging and Director of the Integrative Cancer Therapies Fellowship, will present preliminary findings of a novel technique for treating advanced-stage cancer. Dr. Rosenberg will be sharing his findings at the Fellowship in Integrative Cancer Therapies taking place March 10-13, 2011 in Boca Raton, FL. Boca Raton, FL...

2011-01-04 05:00:00

MANHATTAN BEACH, Calif., Jan. 4, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced that it closed private offerings in December and October 2010 pursuant to which it entered into definitive agreements with accredited investors to purchase a total of 845,000 shares of the Genesis Biopharma common stock for a purchase price of $1.00 per share. Investors in both financings were granted...

2010-12-15 14:59:52

University of Colorado-developed treatment effective in Phase 2 Trials in a biomarker-selected group of patients A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results presented today from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals. The phase 2 results show that the combination of entinostat (Syndax's...

2010-11-10 07:00:00

MANHATTAN BEACH, Calif., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, has formed Genesis Advanced Development Programs (Genesis ADP) to initiate and promote drug development collaborations with leading academic researchers. An initial focus of Genesis ADP will be screening libraries of approved drugs for their use in low-cost development of cocktail drug therapies. "The...

2010-10-12 10:54:00

THE WOODLANDS, Texas, Oct. 12 /PRNewswire/ -- US Oncology, Inc., the nation's leading integrated oncology company, announced today that it has enrolled the 1,000th patient in a Phase I clinical trial through its US Oncology Research Network. Phase I clinical trials present special challenges, including increased safety concerns, higher variability of patient disease, more complex trial designs, and some first-in-human trials, making Phase I trials more difficult to operate in the community...

2010-08-19 09:00:00

THE WOODLANDS, Texas, Aug. 19 /PRNewswire/ -- US Oncology, Inc., the nation's leading integrated oncology company, announced today that in less than two decades it has played a role in the development of 42 novel cancer therapies approved by the US Food and Drug Administration (FDA). (Logo: http://photos.prnewswire.com/prnh/20100517/DA06089LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100517/DA06089LOGO) Tasigna® (nilotinib) capsules, a medicine developed by...

2010-08-05 15:01:00

Conference Call on Thursday, August 5, 2010 at 4:30 p.m. Eastern Time BOTHELL, WA and VANCOUVER, Aug. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the three and six months ended June 30, 2010 and reviewed the Company's highlights for the second quarter of 2010. The Company reported net income of $0.2 million for the quarter ended June 30, 2010. Net loss before income taxes for the...

2010-08-03 05:00:00

SANTA ROSA, Calif., Aug. 3 /PRNewswire/ -- Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies. Lead researcher Dr. Aaron Katz says the findings, "demonstrate that this specific mixture is able to stop abnormal cell growth and induce apoptosis (programmed cell death) in both hormone sensitive and hormone...

2010-07-02 06:00:00

SANTA ROSA, Calif., July 2 /PRNewswire/ -- Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the most recent publication of Integrative Cancer Therapies(1), show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and...

2010-05-20 07:00:00

SANTA ROSA, Calif., May 20 /PRNewswire/ -- Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the online-first publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.